Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Sponsor: Genentech, Inc.
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
Official title: A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2026-04-29
Completion Date
2027-12-30
Last Updated
2026-07-09
Healthy Volunteers
No
Interventions
GDC-1261
Participants will receive GDC-1261 as per the schedule described in the protocol.
Locations (4)
Honor Health Research Institute
Scottsdale, Arizona, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Austin Hospital
Heidelberg, Victoria, Australia